Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the “Transactions”).
The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:
| Employee | Company Position | Transaction Volume | Purchase Price |
|---|
| Tim McCarthy |
Chairman |
49,382 |
13.50p |
| Simon Ward |
CEO |
51,593 |
13.50p |
| Pawel Zolnierzyck |
COO |
11,307 |
13.20p |
| Laura Brogden |
CFO |
15,057 |
13.15p |
| Suzanne Brocks |
Head of Communications |
50,000 |
13.00p |
Total Shareholdings following the Transactions:
| Employee | Company Position | Total Shareholding | % of Share Capital |
|---|
| Tim McCarthy |
Chairman |
3,931,646 |
5.31% |
| Simon Ward |
CEO |
2,704,199 |
3.65% |
| Pawel Zolnierzyck |
COO |
669,544 |
3.65% |
| Laura Brogden |
CFO |
46,034 |
0.06% |
| Suzanne Brocks |
Head of Communications |
325,594 |
0.44% |
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers
+44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney
+44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
Download the announcement in full